

Genervon Biopharmaceutical's Regulator Drug GM6 modulates 238 ALS, 68 AD and 59 PD associated defective genes to bring homeostasis for the respective patient groups

Genervon is a late clinical stage biopharmaceutical company and is ready to out license ALS, AD, PD and a pipeline of other neurological and neurodegenerative disease and disorders. 20 years ago, Genervon decided to abandon the conventional drug development paradigm in the fields of "single gene/target reductionism." Genervon embraced a system biology approach in finding a cure for the highly complex heterogeneous neurodegenerative and neurological diseases and disorders.

Rather than custom designing manmade molecules to target specific defective genes, Genervon looked for and discovered a critical regulator of the human nervous system and named it GM6. GM6 does not act solely as an agonist or antagonist. GM6 is not a cocktail of different molecules. It is an endogenous embryonic stage tyrosine kinase motoneuronotrophic factor regulator. GM6 binds to the insulin receptors, IGF1 receptors, and IGF2 receptors of the human nervous system.

Genervon developed this disruptive medical technology platform with the discovery of the endogenous embryonic stage multi-target regulator GM6 that can bring homeostasis to most nervous system diseases and disorders. For example, GM6 modulates 238 ALS, 68 AD and 59 PD associated defective genes to bring homeostasis for the respective patient groups. The uniform failure of curative ALS trials is a testimony that the pervasive and dominating drug development paradigm of single gene/target reductionism cannot cure ALS and other neurological diseases.

1. Find out more about Genervon: <https://genervon.squarespace.com/about>

2. Advanced researchers now recognize the need for multiple-target drugs for neurodegenerative diseases:
[http://www.trci.alzdem.com/article/S2352-8737\(16\)30037-3/pdf](http://www.trci.alzdem.com/article/S2352-8737(16)30037-3/pdf)

3. Genervon Releases ALS, PD and AD Disease-Associated Gene Lists Modulated by GM6:

<http://www.businesswire.com/news/home/20170110005650/en>

Amyotrophic Lateral Sclerosis (ALS, 89 to 238 genes, 2 to 1.5 folds): <https://f1000research.com/posters/5-2836>

Alzheimer's disease (AD, 48 to 68 genes, 2 to 1.5 folds): <https://f1000research.com/posters/5-2915>

Parkinson's disease (PD 46 to 59 genes, 2 to 1.5 folds): <https://f1000research.com/posters/6-28>

4. TV Special documenting an ALS patient treated with GM604 in Genervon's Phase 2A trial:

<https://execvid.wistia.com/medias/lxq43p0f85>

5. VICE "Debrief on Living with ALS" by a journalist treated with GM604:

https://www.youtube.com/watch?v=NSl_kEU1JAs,

<https://youtu.be/DCKD3KiCUxc>

6. International ALS patient case reports: <https://www.genervon.com/news/2017/10/20/genervon-case-report-update-from-international-als-patients>

7. Orphan Drug and Fast Track Designations from FDA and EMA:

<https://www.dropbox.com/s/k1y1a801dflc53o/GM604-%20EMA%20Orphan%20Drug%20Designation%20PSO.pdf?dl=0>

8. Discovery of GM6, an endogenous regulator of the human nervous system:

<https://www.dropbox.com/s/3xb3hpyrqcnmhv/Genervon%20GM6%2020170209.pptx?dl=0>

9. Tripartite Mechanism of Action of GM6:

<https://www.dropbox.com/s/oooux7lwdbcwdz0/Tripartite%20Mechanism%20of%20Action%20of%20GM6.pdf?dl=0>

10. From Single Gene/Target Reductionism paradigm to System Biology approach to Drug Development for neurological and neurodegenerative diseases and disorders:

<https://www.dropbox.com/s/gfpogl4ggfx8zg/From%20Single%20Target%20reductionism%20to%20system%20biology.pdf?dl=0>